211 related articles for article (PubMed ID: 11595726)
41. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1.
Flørenes VA; Bhattacharya N; Bani MR; Ben-David Y; Kerbel RS; Slingerland JM
Oncogene; 1996 Dec; 13(11):2447-57. PubMed ID: 8957087
[TBL] [Abstract][Full Text] [Related]
42. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
[TBL] [Abstract][Full Text] [Related]
43. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
44. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.
Kamoshida S; Matsuoka H; Shiogama K; Matsuyama A; Shimomura R; Inada K; Maruta M; Tsutsumi Y
Pathol Int; 2004 Aug; 54(8):564-75. PubMed ID: 15260847
[TBL] [Abstract][Full Text] [Related]
46. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma.
Matsuda Y; Ichida T; Genda T; Yamagiwa S; Aoyagi Y; Asakura H
Clin Cancer Res; 2003 Aug; 9(9):3389-96. PubMed ID: 12960127
[TBL] [Abstract][Full Text] [Related]
47. Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells.
Ramirez RD; Herbert BS; Vaughan MB; Zou Y; Gandia K; Morales CP; Wright WE; Shay JW
Oncogene; 2003 Jan; 22(3):433-44. PubMed ID: 12545164
[TBL] [Abstract][Full Text] [Related]
48. Expression of p16INK4a suppresses the unbounded and anchorage-independent growth of a glioblastoma cell line that lacks p16INK4a.
Higashi H; Suzuki-Takahashi I; Yoshida E; Nishimura S; Kitagawa M
Biochem Biophys Res Commun; 1997 Feb; 231(3):743-50. PubMed ID: 9070885
[TBL] [Abstract][Full Text] [Related]
49. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
50. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Zhang B; Peng ZY
Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
[TBL] [Abstract][Full Text] [Related]
51. Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer.
Agarwal P; Sandey M; DeInnocentes P; Bird RC
J Cell Biochem; 2013 Jun; 114(6):1355-63. PubMed ID: 23238983
[TBL] [Abstract][Full Text] [Related]
52. Analysis of p16INK4a and its interaction with CDK4.
Yang R; Serrano M; Slater J; Leung E; Koeffler HP
Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
[TBL] [Abstract][Full Text] [Related]
53. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
54. Wild type and melanoma-associated mutant p16(IN4a) proteins do not oligomerize in vivo.
McKenzie H; Becker TM; Scurr LL; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2009 Feb; 22(1):131-3. PubMed ID: 19154236
[No Abstract] [Full Text] [Related]
55. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
Zuo L; Weger J; Yang Q; Goldstein AM; Tucker MA; Walker GJ; Hayward N; Dracopoli NC
Nat Genet; 1996 Jan; 12(1):97-9. PubMed ID: 8528263
[No Abstract] [Full Text] [Related]
56. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Santamariña M; Hernández G; Zalvide J
Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
[TBL] [Abstract][Full Text] [Related]
57. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
58. Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors.
Mori N; Yang R; Kawamata N; Miller CW; Mizoguchi H; Koeffler HP
Int J Hematol; 2003 Apr; 77(3):259-62. PubMed ID: 12731669
[TBL] [Abstract][Full Text] [Related]
59. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status.
Rheinwald JG; Hahn WC; Ramsey MR; Wu JY; Guo Z; Tsao H; De Luca M; Catricalà C; O'Toole KM
Mol Cell Biol; 2002 Jul; 22(14):5157-72. PubMed ID: 12077343
[TBL] [Abstract][Full Text] [Related]
60. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
